8 / 18
Inst itut Català d'Oncologia
Institut Català d’Oncol gia
Overall Survival by Tumor PD-L1 Expression and
PD-L1
+
TAIC Abundance
Tumor PD-L1 ≥1% & PD-L1
+
TAIC Abundance
Tumor PD-L1 <1% & PD-L1
+
TAIC Abundance
• Tumor PD-L1 ≥1% and rare PD-L1
+
TAICs: mOS increased with NIVO vs IC (6.7 vs 4.9 months, HR 0.89 [0.44, 1.80])
• Tumor PD-L1 <1% and rare PD-L1
+
TAICs: no difference mOS with NIVO vs IC (3.7 vs 4.9 months, HR 1.09 [0.50, 2.36])
•1.0
•0.8
•0.2
•0.0
•0.6
•0.4
•
Survival probability
•5
•10
•0
•20
•25
•15
•
Months
•29
•22
•43
•2
•0
•11
•15
•8
•25
•1
•4
•
NIV
O
•
IC
•Patients at risk
•
mOS IC: 4.60 (95% CI: 3.81, 6.24)
•
mOS NIVO: 9.10 (95% CI: 7.03, 11.56)
•
HR: 0.43 (0.28, 0.67)
•
mOS NIVO: 11.73 (95% CI: 5.16, 15.57)
•
mOS IC: 6.51 (95% CI: 4.01, 10.61)
•
HR: 0.67 (0.38, 1.18)
•1.0
•0.8
•0.2
•0.0
•0.6
•0.4
•
Survival probability
•5
•10
•0
•20
•25
•15
•
Months
•41
•25
•61
•6
•0
•14
•21
•6
•47
•0
•2
•
NIV
O
•
IC
•Patients at risk
•0
•
[Tumor PD-L1 ≥1% HR: 0.55 (0.37, 0.77)]
•
[Tumor PD-L1 <1% HR: 0.83 (0.54, 1.29)]
•Ferris et al. AACR 2017